Innovative Partnership to Evaluate Evidence-Based Insights in
the Optimization of GLP-1 Treatments
HOUSTON and DELRAY
BEACH, Fla., June 20,
2024 /PRNewswire/ -- Aranscia, a leading provider of
personalized diagnostic solutions, and Signature RX, a leading
pharmacy supplier and 503B
manufacturer, today announced a partnership to develop novel
biomarkers and a personalized medication management solution for
the effective use of GLP-1 medications. Under this multi-phase
partnership, Aranscia and Signature RX will help foster continued
research and development into the specific pharmacogenomic (PGx)
and biomarker pathways for GLP-1 receptor agonists, incorporate
evidence-based insights into existing medication management
programs, and support the unmet supply chain needs to ensure
patients preserve steady access to critical medications.
Originally developed for the treatment of Type 2 diabetes,
GLP-1s are a class of medications that are increasingly utilized
for the management of other chronic diseases such as obesity. While
many GLP-1 patients have achieved satisfactory results, variances
in efficacy, side effects, and long-term adherence may be explained
through individual metabolic responses. Inappropriate or
ineffective use issues are compounded by the current and future
projected shortages of these medications, especially for those who
are most in need of the management of chronic conditions.
AccessDx Laboratory, an Aranscia company, is
dedicating resources to the assessment and development of new
companion diagnostics for GLP-1 medications. Peer-reviewed studies
to date have indicated multiple PGx and biomarker pathways that may
benefit further exploration, and the AccessDx team will collaborate
with standards organizations with a goal of expanding research as
well as establishing high-evidence frameworks based on those
findings. AccessDx Lab is a CLIA-certified, CAP-accredited,
and NYSDOH-approved diagnostic laboratory with an extensive history
of success in the development and operation of high complexity
molecular genetic tests.
Under this multi-year partnership, Signature RX will also offer
the YouScript Personalized Medication Management Program to
all current and existing clinical clients. YouScript, an
Aranscia company, is a foundational and proven leader in the
effective use of high-evidence PGx insights to improve outcomes and
lower care costs, with impact across a wide range of chronic
conditions and comorbidities often impacting patients with Type 2
diabetes and obesity. As high-evidence GLP-1 markers become
available, it is envisioned that Signature RX healthcare partners
will be able to use those insights to assist them in optimizing
their patient's GLP-1 medications.
"We're pleased to announce this innovative collaboration with
Signature RX," said Bryon Cipriani,
CEO of Aranscia. "The increasing popularity of GLP-1s, especially
when unchecked against inappropriate or ineffective use, leads to
runaway cost issues, supply chain challenges, and poor therapeutic
outcomes that are detrimental to our care ecosystem. We're proud to
make a commitment to the exploration of companion diagnostics with
AccessDx Lab, and at the opportunity to leverage
YouScript's proven framework for success in personalized
medication management."
"Aranscia is an ideal partner for bringing a comprehensive,
personalized approach to GLP-1s," said David Hughes, PharmD, R.Ph., ABAAHP, PAHM, Chief
Executive Officer of Signature RX. "The massive demand of GLP-1s
must be balanced by clinical initiatives that help providers and
payers ensure patients are on the right drug, and the right dose.
This approach will help Signature RX client organizations ensure
impactful medications are available to those who will truly
benefit, and open new opportunities for programs focused on
combinatorial, cost-effective outcomes improvement across all
medications and disease states," added Hughes.
Organizations who wish to learn more, or participate in the
Aranscia/Signature RX GLP-1 initiatives, can contact
info@aranscia.com.
About Aranscia: Aranscia delivers world-class
diagnostic software, services, and testing innovations that help
clinicians improve care outcomes. The Aranscia portfolio of
companies, which includes 2bPrecise, AccessDx
Laboratory, SinguLab, and YouScript, have
extensive practical expertise in molecular diagnostics, genomics,
and digital-first clinical workflows. Aranscia enables clinical
organizations to effectively utilize precision diagnostics for
turnkey programs in fields such as pharmacogenomics, infectious
disease management, precision oncology, and genetic screening. With
a dual focus on simplicity and scalability, Aranscia's portfolio
companies are the ideal partner for long-term, value-based
precision medicine initiatives. For more information, please visit
www.aranscia.com
About Signature RX: Signature RX is a leading provider of
pharmaceutical manufacturing and distribution services. With a
focus on quality, efficiency, and commitment to patient care,
Signature RX is a trusted partner and resource in helping to
navigate and overcome today's challenges in the pharmacy supply
chain. Signature's 503B services
adhere to the most stringent processes for manufacturing and
quality control, helping to ensure critical access, quality care,
and cost savings for healthcare partners. For more
information, please visit www.signature-rx.com
Media Contact:
Karina Stabile
516-317-5835
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aranscia-and-signature-rx-announce-personalized-medication-management-program-for-glp-1s-302176988.html
SOURCE Aranscia